drugset / Trial / NCT00481923

Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients

NCT00481923

Phase 3 Completed 156 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to assess the effect of rimonabant on the energy intake (kcal/day/meal) from ad-libitum high-fat dinner (primary endpoint), pre- and post-ingestive responses, and the hedonic evaluation of food, and its effect on food choice, cravings and feelings of control. The secondary objectives are to determine the effect of rimonabant on body weight with or without hypocaloric diet and its clinical and laboratory safety.

Timeline

Start
2004-05
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Rimonabant Small molecule 20 mg

Indications